Lead Product(s) : Tanimilast
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Chiesi Presents Data Showcasing Depth of Respiratory Leadership at the ATS 2024 Conference
Details : CHF6001 (tanimilast) is an inhaled phosphodiesterase-4 inhibitor, small molecule drug candidate which is currently being evaluated for the treatment of COPD and asthma.
Product Name : CHF6001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 16, 2024
Lead Product(s) : Tanimilast
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Liposomal Cyclosporine A
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Pari
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : L-CsA-i (Liposomal Cyclosporine A) is a novel, inhaled therapy administered via the optimized investigational eFlow® Technology nebulizer system (PARI Pharma GmbH) for the treatment of BOS in adults following single lung (BOSTON-1) or double lung (BOSTO...
Product Name : L-CsA
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
January 05, 2023
Lead Product(s) : Liposomal Cyclosporine A
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Pari
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zambon Announces Attendance at American Thoracic Society (ATS) 2022 Annual Meeting
Details : Colistimethate sodium (CMS) is a pro-drug (the form used for inhalation therapy) of the antibiotic colistin. Colistin is a polymyxin antibiotic derived from Bacillus polymyxa var. colistinus.
Product Name : Promixin
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Promixin (Colistimethate Sodium) is an investigational treatment being developed as a potential first-in-class inhaled therapy for adult patients with NCFB colonized with P. aeruginosa; NCFB is a chronic, progressive, and irreversible respiratory disease...
Product Name : Promixin
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 21, 2022
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data shows inhalation via the I-neb ® Adaptive Aerosol Delivery System of Promixin (colistimethate sodium) results in reduction of pulmonary exacerbations in non-cystic fibrosis bronchiectasis (NCFB) patients compared to placebo.
Product Name : Promixin
Product Type : Antibiotic
Upfront Cash : Inapplicable
August 09, 2021
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A new FDA Fast Track designation for Zambon
Details : FDA has granted Fast Track designation to Liposomal Cyclosporine A for Inhalation (L‑CsA‑i), in late-stage clinical development for the treatment of Bronchiolitis Obliterans Syndrome.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
April 28, 2020
Lead Product(s) : Cyclosporine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company initiated BOSTON-4 phase 2 multi-center clinical study of Liposomal Cyclosporine A for Inhalation (L‑CsA‑i) for the treatment of bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic stem cell transplant (alloHSCT).
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
February 20, 2020
Lead Product(s) : Cyclosporine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable